Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
CANF similar filings
- 2 May 22 Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
- 5 Apr 22 Current Report of Foreign Private Issuer
- 24 Mar 22 Can-Fite Reports 2021 Financial Results & Provides Clinical Update
- 14 Mar 22 Broad patent addresses markets for the treatment of all advanced liver fibrosis indications
- 11 Mar 22 Can-Fite’s Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv
- 8 Mar 22 Can-Fite’s Phase III Psoriasis Study Data Expected Q2 2022
- 31 Jan 22 Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
Filing view
External links